tiprankstipranks
Zymeworks Inc (ZYME)
NASDAQ:ZYME
US Market
ZYME
Zymeworks
RESEARCH TOOLSreports
Want to see ZYME full AI Analyst Report?

Zymeworks (ZYME) Stock Forecast & Price Target

651 Followers
See the Price Targets and Ratings of:

ZYME Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Zymeworks
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ZYME Stock 12 Month Forecast

Average Price Target

$40.20
▲(46.34% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Zymeworks in the last 3 months. The average price target is $40.20 with a high forecast of $55.00 and a low forecast of $32.00. The average price target represents a 46.34% change from the last price of $27.47.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","56":"$56","23.75":"$23.8","34.5":"$34.5","45.25":"$45.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$32.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,23.75,34.5,45.25,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.67,31.61846153846154,33.566923076923075,35.51538461538462,37.463846153846156,39.41230769230769,41.36076923076923,43.309230769230766,45.25769230769231,47.206153846153846,49.15461538461538,51.10307692307693,53.051538461538456,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.67,30.48,31.290000000000003,32.1,32.910000000000004,33.72,34.53,35.34,36.150000000000006,36.96,37.77,38.58,39.39,{"y":40.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.67,29.849230769230772,30.02846153846154,30.20769230769231,30.38692307692308,30.566153846153846,30.745384615384616,30.924615384615386,31.103846153846156,31.283076923076923,31.462307692307693,31.641538461538463,31.82076923076923,{"y":32,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.01,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.085,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.33,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.17,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.31,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.94,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.61,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.54,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.72,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.94,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.67,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$55.00Average Price Target$40.20Lowest Price Target$32.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on ZYME
Brian Cheng
J.P. Morgan
J.P. Morgan
$31→$33
Buy
20.13%
Upside
Reiterated
09/03/26
Zymeworks price target raised to $33 from $31 at JPMorganZymeworks price target raised to $33 from $31 at JPMorgan
H.C. Wainwright Analyst forecast on ZYME
Robert Burns
H.C. Wainwright
H.C. Wainwright
$51→$55
Buy
100.22%
Upside
Reiterated
08/26/26
Zymeworks price target raised to $55 from $51 at H.C. WainwrightZymeworks price target raised to $55 from $51 at H.C. Wainwright
Citi Analyst forecast on ZYME
Yigal Nochomovitz
Citi
Citi
$37→$38
Buy
38.33%
Upside
Reiterated
08/26/26
Zymeworks price target raised to $38 from $37 at CitiZymeworks price target raised to $38 from $37 at Citi
Bloom Burton Analyst forecast on ZYME
David Martin PhD
Bloom Burton
Bloom Burton
$36→$37
Buy
34.69%
Upside
Reiterated
08/26/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Revolution Medicines (NASDAQ: RVMD) and Agilent (NYSE: A)
Wells Fargo Analyst forecast on ZYME
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$40
Buy
45.61%
Upside
Assigned
08/25/26
Analysts Are Bullish on These Healthcare Stocks: Zymeworks (ZYME), Johnson & Johnson (JNJ)
LifeSci Capital Analyst forecast on ZYME
Charles Zhu
LifeSci Capital
LifeSci Capital
$34
Buy
23.77%
Upside
Reiterated
08/25/26
Analysts Are Bullish on These Healthcare Stocks: Zymeworks (ZYME), Jazz Pharmaceuticals (JAZZ)
Truist Financial Analyst forecast on ZYME
Gregory Renza
Truist Financial
Truist Financial
$32
Buy
16.49%
Upside
Reiterated
08/11/26
Truist Financial Keeps Their Buy Rating on Zymeworks (ZYME)
Stifel Nicolaus Analyst forecast on ZYME
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$46
Buy
67.46%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME) and Edgewise Therapeutics (NASDAQ: EWTX)
B. Riley Securities Analyst forecast on ZYME
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$40→$44
Buy
60.17%
Upside
Reiterated
08/10/26
Zymeworks price target raised to $44 from $40 at B. RileyZymeworks price target raised to $44 from $40 at B. Riley
Jefferies Analyst forecast on ZYME
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$43
Buy
56.53%
Upside
Reiterated
06/30/26
Jefferies Sticks to Their Buy Rating for Zymeworks (ZYME)
TD Cowen Analyst forecast on ZYME
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/08/26
Zymeworks: Strong Ziihera Royalty Momentum and Deep Oncology Pipeline Underpin Buy Rating and Favorable Risk-Reward
Evercore ISI Analyst forecast on ZYME
Jonathan Miller
Evercore ISI
Evercore ISI
$33→$48
Buy
74.74%
Upside
Reiterated
03/09/26
Evercore ISI Sticks to Its Buy Rating for Zymeworks (ZYME)
Citizens JMP Analyst forecast on ZYME
Reni Benjamin
Citizens JMP
Citizens JMP
$32
Buy
16.49%
Upside
Initiated
12/03/25
Zymeworks initiated with an Outperform at Citizens JMPZymeworks initiated with an Outperform at Citizens JMP
Leerink Partners Analyst forecast on ZYME
Andrew Berens
Leerink Partners
Leerink Partners
$37→$40
Buy
45.61%
Upside
Reiterated
11/19/25
Zymeworks price target raised to $37 from $24 at LeerinkZymeworks price target raised to $37 from $24 at Leerink
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on ZYME
Brian Cheng
J.P. Morgan
J.P. Morgan
$31→$33
Buy
20.13%
Upside
Reiterated
09/03/26
Zymeworks price target raised to $33 from $31 at JPMorganZymeworks price target raised to $33 from $31 at JPMorgan
H.C. Wainwright Analyst forecast on ZYME
Robert Burns
H.C. Wainwright
H.C. Wainwright
$51→$55
Buy
100.22%
Upside
Reiterated
08/26/26
Zymeworks price target raised to $55 from $51 at H.C. WainwrightZymeworks price target raised to $55 from $51 at H.C. Wainwright
Citi Analyst forecast on ZYME
Yigal Nochomovitz
Citi
Citi
$37→$38
Buy
38.33%
Upside
Reiterated
08/26/26
Zymeworks price target raised to $38 from $37 at CitiZymeworks price target raised to $38 from $37 at Citi
Bloom Burton Analyst forecast on ZYME
David Martin PhD
Bloom Burton
Bloom Burton
$36→$37
Buy
34.69%
Upside
Reiterated
08/26/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Revolution Medicines (NASDAQ: RVMD) and Agilent (NYSE: A)
Wells Fargo Analyst forecast on ZYME
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$40
Buy
45.61%
Upside
Assigned
08/25/26
Analysts Are Bullish on These Healthcare Stocks: Zymeworks (ZYME), Johnson & Johnson (JNJ)
LifeSci Capital Analyst forecast on ZYME
Charles Zhu
LifeSci Capital
LifeSci Capital
$34
Buy
23.77%
Upside
Reiterated
08/25/26
Analysts Are Bullish on These Healthcare Stocks: Zymeworks (ZYME), Jazz Pharmaceuticals (JAZZ)
Truist Financial Analyst forecast on ZYME
Gregory Renza
Truist Financial
Truist Financial
$32
Buy
16.49%
Upside
Reiterated
08/11/26
Truist Financial Keeps Their Buy Rating on Zymeworks (ZYME)
Stifel Nicolaus Analyst forecast on ZYME
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$46
Buy
67.46%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME) and Edgewise Therapeutics (NASDAQ: EWTX)
B. Riley Securities Analyst forecast on ZYME
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$40→$44
Buy
60.17%
Upside
Reiterated
08/10/26
Zymeworks price target raised to $44 from $40 at B. RileyZymeworks price target raised to $44 from $40 at B. Riley
Jefferies Analyst forecast on ZYME
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$43
Buy
56.53%
Upside
Reiterated
06/30/26
Jefferies Sticks to Their Buy Rating for Zymeworks (ZYME)
TD Cowen Analyst forecast on ZYME
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/08/26
Zymeworks: Strong Ziihera Royalty Momentum and Deep Oncology Pipeline Underpin Buy Rating and Favorable Risk-Reward
Evercore ISI Analyst forecast on ZYME
Jonathan Miller
Evercore ISI
Evercore ISI
$33→$48
Buy
74.74%
Upside
Reiterated
03/09/26
Evercore ISI Sticks to Its Buy Rating for Zymeworks (ZYME)
Citizens JMP Analyst forecast on ZYME
Reni Benjamin
Citizens JMP
Citizens JMP
$32
Buy
16.49%
Upside
Initiated
12/03/25
Zymeworks initiated with an Outperform at Citizens JMPZymeworks initiated with an Outperform at Citizens JMP
Leerink Partners Analyst forecast on ZYME
Andrew Berens
Leerink Partners
Leerink Partners
$37→$40
Buy
45.61%
Upside
Reiterated
11/19/25
Zymeworks price target raised to $37 from $24 at LeerinkZymeworks price target raised to $37 from $24 at Leerink
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
BLTEBelite Bio, Inc. ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zymeworks

3 Months
Charles ZhuLifeSci Capital
Success Rate
13/16 ratings generated profit
81%
Average Return
+18.90%
Copying Charles Zhu's trades and holding each position for 3 Months would result in 81.25% of your transactions generating a profit, with an average return of +18.90% per trade.
1 Year
Charles ZhuLifeSci Capital
Success Rate
16/16 ratings generated profit
100%
Average Return
+59.30%
Copying Charles Zhu's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +59.30% per trade.
2 Years
Yigal NochomovitzCiti
Success Rate
16/16 ratings generated profit
100%
Average Return
+88.31%
Copying Yigal Nochomovitz's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +88.31% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZYME Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
11
9
5
12
9
Buy
10
15
14
17
9
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
24
19
29
18
In the current month, ZYME has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ZYME average Analyst price target in the past 3 months is 40.20.
Each month's total comprises the sum of three months' worth of ratings.

ZYME Financial Forecast

ZYME Earnings Forecast

Next quarter’s earnings estimate for ZYME is $2.42 with a range of -$0.57 to $3.39. The previous quarter’s EPS was -$0.62. ZYME beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ZYME has Performed in-line its overall industry.
Next quarter’s earnings estimate for ZYME is $2.42 with a range of -$0.57 to $3.39. The previous quarter’s EPS was -$0.62. ZYME beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ZYME has Performed in-line its overall industry.

ZYME Sales Forecast

Next quarter’s sales forecast for ZYME is $231.88M with a range of $4.16M to $277.00M. The previous quarter’s sales results were $4.59M. ZYME beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ZYME has Performed in-line its overall industry.
Next quarter’s sales forecast for ZYME is $231.88M with a range of $4.16M to $277.00M. The previous quarter’s sales results were $4.59M. ZYME beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ZYME has Performed in-line its overall industry.

ZYME Stock Forecast FAQ

What is ZYME’s average 12-month price target, according to analysts?
Based on analyst ratings, Zymeworks Inc’s 12-month average price target is 40.20.
    What is ZYME’s upside potential, based on the analysts’ average price target?
    Zymeworks Inc has 46.34% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ZYME a Buy, Sell or Hold?
          Zymeworks Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Zymeworks Inc’s price target?
            The average price target for Zymeworks Inc is 40.20. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $55.00 ,the lowest forecast is $32.00. The average price target represents 46.34% Increase from the current price of $27.47.
              What do analysts say about Zymeworks Inc?
              Zymeworks Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of ZYME?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.